{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"67.44","upperLimit":"79.49","value":"73.47"},{"groupId":"OG001","lowerLimit":"64.37","upperLimit":"73.34","value":"68.86"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48.94","upperLimit":"63.42","value":"56.18"},{"groupId":"OG001","lowerLimit":"47.15","upperLimit":"57.48","value":"52.32"}]}],"title":"18 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"431"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Participants will receive placebo matching to atezolizumab via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg/m\\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo and Paclitaxel"},{"description":"Participants will receive atezolizumab at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg per square meter (mg/m\\^2) via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab and Paclitaxel"}],"paramType":"NUMBER","populationDescription":"ITT population: all randomized participants, whether or not the assigned study treatment was received","reportingStatus":"POSTED","timeFrame":"From Day 1 to death from any cause, assessed up to 12 and 18 months","title":"Percentage of Participants Who Are Alive at 12 and 18 Months","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}